Rameda commences manufacture of “Anviziram” Tablets the Generic Equivalent of Japanese antiviral Avigan for treatment of Covid-19 patients and receives approval from Egyptian Drug Authority to manufacture Remedsivir Corporate NewsBy adminJune 22, 2020
EGX disclosure regarding Rameda’s manufacturing of “Anviziram” Tablets the Generic Equivalent of Japanese antiviral Avigan for treatment of Covid-19 patients and receives approval from Egyptian Drug Authority to manufacture Remedsivir Regulatory DisclosuresBy adminJune 22, 2020
Details Standalone financial statements for the period ended 31 March 2020Standalone Financial StatementsBy adminMay 17, 2020
Details Consolidated financial statements for the period ended 31 March 2020Consolidated Financial Statements resultsBy adminMay 17, 2020
